Administrative Supplement: Mechanistic and Pharmacologic Studies of Selective Mithramycin Analogues Targeting EWS-FLI1 in Ewing Sarcoma

Medicine and Dentistry

1. Plicamycin 100%
2. Leukemia 60%
3. Tumor Immunity 50%
4. T Cell 50%
5. Leukemia Cell 40%
6. Aptitude 40%
7. Malignant Neoplasm 40%
8. Growth 30%
9. Tumor Cell 30%
10. Neoplasm 30%
11. Lymphoma 30%
12. Cells 30%
13. Cancer Cell 30%
14. Chimeric Antigen Receptor T-Cell 20%
15. Antibody 20%
16. Cytokine 20%
17. Secretion (Process) 20%
18. Pharmacokinetics 10%
19. Laboratory 10%
20. CTLA-4 10%
21. Nodular Melanoma 10%
22. Immunocompetent Cell 10%
23. Reporter Gene 10%
24. Cytotoxicity 10%
25. Cellular Immunity 10%
26. Ewing Sarcoma 10%
27. Programmed Death-Ligand 1 10%
28. Diffuse Large B-Cell Lymphoma 10%
29. Monitoring 10%
30. T-Cell Response 10%
31. Adult 10%
32. Hematological Cancer 10%
33. Specific Tumor 10%
34. Lung Cancer 10%
35. Parent 10%
36. T Lymphocyte Receptor 10%
37. Evaluation Study 10%
38. Adoptive Transfer 10%
39. Gene Expression 10%
40. Chemotherapy Agent 10%
41. Cell Growth 10%
42. T Cell Subset 10%
43. Child 10%
44. B-Cell Chronic Lymphocytic Leukemia 10%